From the Research
Testosterone cypionate should be prescribed for postmenopausal women with hypoactive sexual desire disorder at doses of 0.5-1.0 mg per day, which translates to approximately 50-100 mg injected intramuscularly every 3-4 weeks, as supported by the most recent and highest quality study available 1.
Key Considerations
- Treatment should start at the lower dose and be adjusted based on symptom response and serum testosterone levels, aiming for the lower half of the normal range for premenopausal women (15-70 ng/dL) 2.
- Before initiating therapy, baseline hormone levels should be measured, and regular monitoring should occur at 3-6 month intervals during treatment 2.
- Side effects to watch for include acne, hirsutism, voice deepening, and potential cardiovascular effects 3, 2.
- It's essential to note that testosterone use in women is considered off-label in many countries, as most testosterone preparations are FDA-approved only for men 1, 2.
Rationale
The decision to use testosterone cypionate in postmenopausal women is based on the potential benefits of improving sexual function, energy levels, and potentially bone density, while minimizing the risks of adverse effects 3, 1, 2.
- The evidence from studies suggests that testosterone therapy can improve sexual function in postmenopausal women, particularly those with hypoactive sexual desire disorder 3, 1.
- However, the use of testosterone in women is not without risks, and careful monitoring and individualized treatment are necessary to minimize adverse effects 3, 2.
Monitoring and Adjustment
- Regular monitoring of serum testosterone levels, as well as assessment of symptom response and potential adverse effects, is crucial to adjust the dose and ensure the safe and effective use of testosterone cypionate 2.
- The goal of treatment is to achieve the lowest effective dose for the shortest duration necessary to meet therapeutic goals, while minimizing the risk of adverse effects 2.